PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Attana AB

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Attana AB Introduces the Attana Cell 200 - Potentially Improves Drug Development - Attana Cell 200 – the first system to permit real-time kinetic analysis of molecular interactions directly on cell surfaces, bringing drug development a step closer to the body
Attana AB Introduces the Attana Cell 200 - Potentially Improves Drug Development

 

NewswireToday - /newswire/ - Stockholm, Sweden, 2010/02/01 - Attana Cell 200 – the first system to permit real-time kinetic analysis of molecular interactions directly on cell surfaces, bringing drug development a step closer to the body.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

As the first company in the world, Attana launches a system measuring molecular interactions label free directly on cell surfaces. In line with Attana’s innovative strategy, the Attana Cell 200 is a revolutionary system that rapidly generates biologically relevant information on molecular interactions with cell surfaces. Thanks to groundbreaking innovations and sedulous developments, Attana is the only player on the market that offers cells integrated as sensor surface. The experiments mimic real life conditions and generate information with higher biological relevance in comparison with traditional synthetic sensor surfaces.

Drug development is financially risky and time consuming. To save money and time the industry needs to early identify and eliminate unsuitable candidates. Attana Cell 200 biosensor system improves the selection process by rapidly identifying promising drug candidates. This enables early and well informed decisions in selecting relevant candidates while reducing unnecessary development costs and saving time. The Attana Cell 200 is label free, can run unpurified candidate molecules and has high throughput, resulting in fast and efficient screening of many drug candidates.

Attana Cell 200 is launched with new applications such as kinetic evaluation of cellular biomolecular interactions, e.g. antibody-receptor and lectin-carbohydrate, competition assays and cell capturing.

About Attana AB

Based in Stockholm, Sweden, Attana AB (attana.com) develops and sells biosensors for analysis of biomolecular interactions. Our systems have since 2003 been employed at leading life science companies and universities worldwide, working in a wide variety of research fields. Attana’s biosensors can be used to determine specificity, kinetics and affinity, amongst other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Attana AB

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Attana AB Introduces the Attana Cell 200 - Potentially Improves Drug Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Gabriela Suhoschi - Attana.com 
+46(0)8 674 57 12 gabriela.suhoschi[.]attana.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Attana AB securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Attana AB / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)